Guilford to Present at CIBC World Markets Annual Biotech & Specialty Pharmaceuticals Conference

Guilford to Present at CIBC World Markets Annual Biotech &
Specialty Pharmaceuticals Conference 


BALTIMORE, April 27  /PRNewswire-FirstCall/ -- Guilford Pharmaceuticals Inc. 
announced today that it will present at the CIBC World Markets Annual Biotech &
Specialty Pharmaceuticals Conference on Wednesday, April 28, 2004 at 9:00 a.m.
EDT at the Millennium Broadway Hotel in New York, NY.

Guilford's Chairman, President and CEO, Craig R. Smith, M.D. will provide an
update on the Company's business as well as new developments on products
currently in the pipeline.

To access the live audio broadcast or the subsequent archived recording log on
to http://www.guilfordpharm.com/.  The link for the webcast is located under
the Investor Relations section of the website under "conferences." Please
connect to the website several minutes prior to the start of the conference
call to ensure adequate time for any software download that may be necessary.

About Guilford

Guilford Pharmaceuticals Inc. is a fully integrated pharmaceutical company
engaged in the research, development and commercialization of products that
target the hospital market.  Presently, Guilford markets two commercial
products, GLIADEL(R) Wafer (polifeprosan 20 with carmustine implant), for the
treatment of brain cancer, and AGGRASTAT(R) Injection (tirofiban
hydrochloride), a glycoprotein GP IIb/IIIa receptor antagonist used for the
treatment of acute coronary syndrome (ACS).  Guilford's product pipeline
includes a novel anesthetic, AQUAVAN(R) Injection, and drugs for treating
Parkinson's disease and post-prostatectomy erectile dysfunction.

CONTACT:  Stacey Jurchison, Director, Corporate Communications, Guilford
Pharmaceuticals, [phone]; . http://www.guilfordpharm.com/. 

DATASOURCE: Guilford Pharmaceuticals Inc.



CONTACT:  Stacey Jurchison, Director, Corporate Communications, Guilford

Pharmaceuticals, [phone], 



Web site:  http://www.guilfordpharm.com/ 



Company News On-Call:  http://www.prnewswire.com/comp/112882.html

Copyright